We found that cirmtuzumab enhances the in vitro cytotoxic activity of venetoclcax for CLL cells with a high-level expression of ROR1, indicating that combining these drugs may have a synergistic effect in CLL patients, by simultaneously targeting ROR1 and Bcl2 in the same leukemic cells [52]. This evidence concerns the gene ROR1 and B-cell chronic lymphocytic leukemia.